Clinical and pathological features of dense deposit disease in Chinese patients

Clinical Nephrology

Volumn 78, Issue 3, 2012, Pages 207-215

  Wang, Jinquan ^a   Tang, Zheng ^a   Luo, Chunlei ^a   Hu, Yanglin ^a   Zeng, Caihong ^a   Chen, Huiping ^a   Liu, Zhihong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Dense deposited disease; Hypocomple; Membrane proliferative glomerulonephritis; Mentemia; Tripterygium wilfordii

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HEPARIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TRIPTERYGIUM WILFORDII EXTRACT;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BIOPSY TECHNIQUE; BOWMAN CAPSULE; CHILD; CHINESE; CLINICAL ARTICLE; DENSE DEPOSIT DISEASE; DISEASE COURSE; DRUG DOSE REDUCTION; ELECTRON MICROSCOPY; FEMALE; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS CAPILLARY; HEMATURIA; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TUBULE BASEMENT MEMBRANE; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MICROSCOPY; PERIODIC ACID SCHIFF STAIN; PRESCHOOL CHILD; PROTEINURIA; RARE DISEASE; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ADULT; ANEMIA; BOWMAN CAPSULE; CHILD; CHINA; COMPLEMENT C3; FEMALE; GLOMERULAR BASEMENT MEMBRANE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEMATURIA; HUMANS; HYPERTENSION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KIDNEY TUBULES; MALE; PHYTOTHERAPY; PLANT PREPARATIONS; PROTEINURIA; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TRIPTERYGIUM; YOUNG ADULT;

EID: 84867670422     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107363     Document Type: Article

References (33)

1. Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone - a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1992; 6: 123-130. doi:10.1007/BF00866289 PubMed
2. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Würzner R et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005; 16: 1392-1403. doi:10.1681/ASN.200 5010078 PubMed
3. McEnery PT. Membranoproliferative glomerulonephritis: the Cincinnati experience - cumulative renal survival from 1957 to 1989. J Pediatr. 1990; 116: S109-S114. doi:10.1016/S0022-3476(05)82712-X PubMed
4. Mao T, Wu K, Yang Y, Hsu H. Prolonged asymptomatic dense deposit disease in Chinese. Report of 2 cases in Taiwan. Am J Nephrol. 1998; 18: 464-468. doi:10.1159/000013373 PubMed
5. Soma J, Sato K, Sakuma T, Saito H, Sato H. Focalsegmental dense deposit disease with prolonged asymptomatic hematuria. Clin Nephrol. 2003; 60: 66-68. PubMed
6. Ikeda M, Honda M, Hasegawa O. Another example of spontaneous improvement in a case of dense deposit disease. Pediatr Nephrol. 2001; 16: 609-610. doi:10.1007/s004670100594 PubMed
7. Marks SD, Rees L. Spontaneous clinical improvement in dense deposit disease. Pediatr Nephrol. 2000; 14: 322-324. doi:10.1007/s004670050768 PubMed
8. Qu LJ, Yu YH, Yu Y, Zhang LF, Zeng L. Ultrastructural observation of dense deposit disease. J Chin Electr Microsc Soc. 2002: 879-884.
9. Wang M, Lin XM, Wang SX, Wang HY, Zou WZ. Clinicopathologic characteristics of dense deposit disease. Chin J Nephrol. 2001; 17: 16-19.
10. Yang YF, Chen W, Chen H, Li A, Zou WZ, Shen YP. A child case with dense deposit disease. Chin J Nephrol. 2005; 21: 342-344.
11. Zhang ZG, Guo MY. A case with dense deposit disease. Chin J Path. 1999; 28: 235-236.
12. Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens. 2007; 16: 204-212. doi:10.1097/MNH.0b013e3280bdc0f4 PubMed
13. Bennett WM, Fassett RG, Walker RG, Fairley KF, d'Apice AJ, Kincaid-Smith P. Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease. Am J Kidney Dis. 1989; 13: 469-476. PubMed
14. Habib R, Gubler MC, Loirat C, Mäiz HB, Levy M. Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int. 1975; 7: 204-215. doi:10.1038/ki.1975.32 PubMed
15. Walker PD, Ferrario F, Joh K, Bonsib SM. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol. 2007; 20: 605-616. doi:10.1038/modpathol.3800773 PubMed
16. Zhou XJ, Silva FG. Membranoproliferative glomerulonephritis.
17. In: Jennette JC, Olson JL, Schwartz MM, Silva FG(eds). Heptistall's pathology of the kidney. Philadelphia: Lippincott Willians & Willkins; 2007. p. 253-319.
18. Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol. 2009; 4: 22-32. doi:10.2215/CJN.03480708 PubMed
19. Sibley RK, Kim Y. Dense intramembranous deposit disease: new pathologic features. Kidney Int. 1984; 25: 660-670. doi:10.1038/ki.1984.71 PubMed
20. Jansen JH, Høgåsen K, Mollnes TE. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol. 1993; 143: 1356-1365. PubMed
21. The Southwest Pediatric Nephrology Study Group. Dense deposit disease in children: prognostic value of clinical and pathologic indicators. Am J Kidney Dis. 1985; 6: 161-169. PubMed
22. Kurtz KA, Schlueter AJ. Management of membranoproliferative glomerulonephritis type II with plasmapheresis. J Clin Apher. 2002; 17: 135-137. doi:10.1002/jca.10026 PubMed
23. Pickering MC, Warren J, Rose KL, Carlucci F, Wang Y, Walport MJ, Cook HT, Botto M. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA. 2006; 103: 9649-9654. doi:10.1073/pnas.0601094103 PubMed
24. Lutz HU, Stammler P, Bianchi V, Trüeb RM, Hunziker T, Burger R, Jelezarova E, Späth PJ. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood. 2004; 103: 465-472. doi:10.1182/blood-2003-05-1530 PubMed
25. Krmar RT, Holtbäck U, Linné T, Berg UB, Celsi G, Söderberg MP, Wernerson A, Szakos A, Larsson S, Skattum L, Bárány P. Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange. Clin Nephrol. 2011; 75 (Suppl 1): 4-10. PubMed
26. Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS, Liu ZH. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int. 2008; 74: 596-612. doi:10.1038/ki.2008.203 PubMed
27. Chen ZH, Qin WS, Zeng CH, Zheng CX, Hong YM, Lu YZ, Li LS, Liu ZH. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int. 2010; 77: 974-988. doi:10.1038/ki.2010.41 PubMed
28. Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, Ng JC, Kao PN. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem.1999; 274: 13443-13450. doi:10.107 4/ jbc.274.19.13443 PubMed
29. Qiu D, Kao PN. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D. 2003; 4: 1-18. doi:10.2165/00126839-2003040 10-0 0001 PubMed
30. Hong Y, Zhou W, Li K, Sacks SH. Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells. Kidney Int. 2002; 62: 1291-1300. doi:10.1 111/j.1523-1755.2002.kid586.x PubMed
31. Tao XL, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am. 2000; 26: 29-50. doi:10.1016/S0889-857X (05)70118-6 PubMed
32. Xu G, Tu W, Jiang D, Xu C. Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis. Nephron Clin Pract. 2009; 111: c223-c228. doi:1 0.1 159/000208990 PubMed
33. Chen YZ, Gao Q, Zhao XZ, Chen XM, Zhang F, Chen J, Xu CG, Sun LL, Mei CL. Meta-analysis of Tripterygium wilfordii Hook F in the immunosuppressive treatment of IgA nephropathy. Intern Med. 2010; 49: 2049-2055. doi:10.2169/internalmedicine.49.3704 PubMed